Sign In
to Vote &
Create Storyboards.
 
(University of Kentucky) In an editorial in CNS Spectrums, a neurologists takes the research community to task for its lack of minority representation in Phase III clinical trials for drugs to treat Multiple Sclerosis (MS) and proposes changes to the system.
2
0
0


Storyboard
Print
Share this Article



Comment on this Article

Please Sign In to comment

Recommended

  • {TITLE}
    {PUBLISHER} - {PUBLISHED_DATE}
    {VIEWS}
  • Create Storyboard